Regeneron Pharmaceuticals (REGN) Revenue (2009 - 2026)
Regeneron Pharmaceuticals' quarterly Revenue came in at $3.6 billion in Q1 2026, up 19.04% year-on-year from $3.0 billion in Q1 2025, and down 7.18% quarter-over-quarter from $3.9 billion in Q4 2025.
Regeneron Pharmaceuticals has reported Revenue for 18 years, with the latest figure at $3.6 billion in Q1 2026.
- For the quarter ending Q1 2026, Revenue rose 19.04% year-over-year to $3.6 billion; the trailing twelve-month figure through Mar 2026 stood at $14.9 billion (up 5.92% YoY), and the FY2025 full-year result was $14.3 billion, up 0.99% from the prior year.
- Revenue for Q1 2026 stood at $3.6 billion, down from $3.9 billion in the prior quarter.
- The five-year high for Revenue was $3.9 billion in Q4 2025, with the low at $50.0 million in Q1 2022.
- Average Revenue over 5 years is $3.0 billion, with a median of $3.4 billion recorded in 2023.
- Year-over-year, Revenue slumped 98.02% in 2022 and soared 6224.2% in 2023.
- Tracing REGN's Revenue over 5 years: stood at $100.0 million in 2022, then soared by 3334.3% to $3.4 billion in 2023, then advanced by 10.33% to $3.8 billion in 2024, then advanced by 2.51% to $3.9 billion in 2025, then fell by 7.18% to $3.6 billion in 2026.
- The last three Revenue figures came in at $3.6 billion (Q1 2026), $3.9 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Revolution Medicines | 31.20 Bn | 31.20 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.61 Bn |
| Dec 31, 2025 | 3.88 Bn |
| Sep 30, 2025 | 3.75 Bn |
| Jun 30, 2025 | 3.68 Bn |
| Mar 31, 2025 | 3.03 Bn |
| Dec 31, 2024 | 3.79 Bn |
| Sep 30, 2024 | 3.72 Bn |
| Jun 30, 2024 | 3.55 Bn |
| Mar 31, 2024 | 3.15 Bn |
| Dec 31, 2023 | 3.43 Bn |
| Sep 30, 2023 | 3.36 Bn |
| Jun 30, 2023 | 3.16 Bn |
| Mar 31, 2023 | 3.16 Bn |
| Dec 31, 2022 | 100.00 Mn |
| Sep 30, 2022 | 2.94 Bn |
| Jun 30, 2022 | 2.86 Bn |
| Mar 31, 2022 | 50.00 Mn |
| Dec 31, 2021 | 4.95 Bn |
| Sep 30, 2021 | 3.45 Bn |
| Jun 30, 2021 | 5.14 Bn |
| Mar 31, 2021 | 2.53 Bn |
| Dec 31, 2020 | 2.42 Bn |
| Sep 30, 2020 | 2.29 Bn |
| Jun 30, 2020 | 1.95 Bn |
| Mar 31, 2020 | 1.83 Bn |
| Dec 31, 2019 | 1.86 Bn |
| Sep 30, 2019 | 1.74 Bn |
| Jun 30, 2019 | 1.58 Bn |
| Mar 31, 2019 | 1.37 Bn |
| Dec 31, 2018 | 1.93 Bn |
| Sep 30, 2018 | 1.66 Bn |
| Jun 30, 2018 | 1.61 Bn |
| Mar 31, 2018 | 1.51 Bn |
| Dec 31, 2017 | 1.58 Bn |
| Sep 30, 2017 | 1.50 Bn |
| Jun 30, 2017 | 1.47 Bn |
| Mar 31, 2017 | 1.32 Bn |
| Dec 31, 2016 | 1.23 Bn |
| Sep 30, 2016 | 1.22 Bn |
| Jun 30, 2016 | 1.21 Bn |
| Mar 31, 2016 | 1.20 Bn |
| Dec 31, 2015 | 1.10 Bn |
| Sep 30, 2015 | 1.14 Bn |
| Jun 30, 2015 | 998.62 Mn |
| Mar 31, 2015 | 869.61 Mn |
| Dec 31, 2014 | 802.33 Mn |
| Sep 30, 2014 | 725.79 Mn |
| Jun 30, 2014 | 665.70 Mn |
| Mar 31, 2014 | 625.74 Mn |
| Dec 31, 2013 | 610.41 Mn |
| Sep 30, 2013 | 597.03 Mn |
| Jun 30, 2013 | 457.64 Mn |
| Mar 31, 2013 | 439.66 Mn |
| Dec 31, 2012 | 414.60 Mn |
| Sep 30, 2012 | 427.69 Mn |
| Jun 30, 2012 | 304.40 Mn |
| Mar 31, 2012 | 231.79 Mn |
| Dec 31, 2011 | 122.98 Mn |
| Sep 30, 2011 | 102.83 Mn |
| Jun 30, 2011 | 107.81 Mn |
| Mar 31, 2011 | 112.20 Mn |
| Dec 31, 2010 | -13.04 Mn |
| Sep 30, 2010 | 4.94 Mn |
| Jun 30, 2010 | 115.89 Mn |
| Mar 31, 2010 | 1.89 Mn |
| Dec 31, 2009 | 13.14 Mn |
| Sep 30, 2009 | 117.46 Mn |
| Jun 30, 2009 | 4.50 Mn |